The utilization of pharmaceutical cannabinoid agents in Manitoba, Canada. A population-based study using administrative health care data.
| dc.contributor.author | Alkabbani, Wajd | |
| dc.contributor.examiningcommittee | Bugden, Shawn (Pharmacy) Alessi-Severini, Silvia (Pharmacy) Marrie, Ruth Ann (Internal Medicine) | en_US |
| dc.contributor.supervisor | Leong, Christine (Pharmacy) | en_US |
| dc.date.accessioned | 2019-03-01T17:19:12Z | |
| dc.date.available | 2019-03-01T17:19:12Z | |
| dc.date.issued | 2019-02 | en_US |
| dc.date.submitted | 2019-03-01T16:36:04Z | en |
| dc.degree.discipline | Pharmacy | en_US |
| dc.degree.level | Master of Science (M.Sc.) | en_US |
| dc.description.abstract | Introduction: Pharmaceutical cannabinoids are third-line therapeutic options for several indications, despite the lack of strong evidence to support their efficacy. The extent and patterns of their utilization from a population perspective are unknown. Methods: A retrospective population-based study using administrative healthcare data from Apr.1, 2004 to Mar.31, 2017, to assess the annual trends, demographic and clinical determinants, and persistence of pharmaceutical cannabinoids use. Results: The incident and prevalent users of cannabinoid agents increased throughout the study period. Nabilone comprised the majority of dispensations. The percent of users who had a diagnosis for the approved indications was relatively low. Persistence of cannabinoid use was low and influenced by the socio-demographics and medical conditions of users. Conclusion: Although the rates of pharmaceutical cannabinoid use have increased, the overall low numbers of users and the high discontinuation rates reflect the lack of effectiveness and tolerability to these agents. | en_US |
| dc.description.note | May 2019 | en_US |
| dc.identifier.citation | Alkabbani W, Marrie RA, Bugden S, Alessi-Severini S, Daeninck P, Bolton JM, Sareen J, Leong, C. Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. CMAJ Open. 2018;6(4):E637-E642. | en_US |
| dc.identifier.uri | http://hdl.handle.net/1993/33777 | |
| dc.language.iso | eng | en_US |
| dc.rights | open access | en_US |
| dc.subject | Drug utilization | en_US |
| dc.subject | Cannabinoids | en_US |
| dc.subject | pharmacoepidemiology | en_US |
| dc.subject | Administrative data | en_US |
| dc.title | The utilization of pharmaceutical cannabinoid agents in Manitoba, Canada. A population-based study using administrative health care data. | en_US |
| dc.type | master thesis | en_US |
| local.subject.manitoba | yes | en_US |